Lifitegrast clinical efficacy for treatment of signs and symptoms of dry eye disease across three randomized controlled trials

scientific article published on 8 July 2016

Lifitegrast clinical efficacy for treatment of signs and symptoms of dry eye disease across three randomized controlled trials is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1080/03007995.2016.1210107
P698PubMed publication ID27388660

P2093author name stringStephen S Lane
Edward J Holland
Aparna Raychaudhuri
Kenneth Sall
Amir Shojaei
Walter O Whitley
Steven Y Zhang
P2860cites workLifitegrast, a Novel Integrin Antagonist for Treatment of Dry Eye DiseaseQ26774853
Associations between signs and symptoms of dry eye disease: a systematic reviewQ26781979
The pharmacologic assessment of a novel lymphocyte function-associated antigen-1 antagonist (SAR 1118) for the treatment of keratoconjunctivitis sicca in dogsQ34165372
Lifitegrast Ophthalmic Solution 5.0% versus Placebo for Treatment of Dry Eye Disease: Results of the Randomized Phase III OPUS-2 StudyQ34493904
Dry eye as a mucosal autoimmune diseaseQ34647761
Safety of Lifitegrast Ophthalmic Solution 5.0% in Patients With Dry Eye Disease: A 1-Year, Multicenter, Randomized, Placebo-Controlled StudyQ36877000
Dry eye disease: an immune-mediated ocular surface disorderQ36916372
Corneal inflammation is inhibited by the LFA-1 antagonist, lifitegrast (SAR 1118)Q40356553
Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 studyQ42708147
Ocular surface APCs are necessary for autoreactive T cell-mediated experimental autoimmune lacrimal keratoconjunctivitis.Q50994458
P407language of work or nameEnglishQ1860
P921main subjecteye diseaseQ3041498
lifitegrastQ23044263
P304page(s)1-24
P577publication date2016-07-08
P1433published inCurrent Medical Research and OpinionQ5195063
P1476titleLifitegrast clinical efficacy for treatment of signs and symptoms of dry eye disease across three randomized controlled trials

Reverse relations

cites work (P2860)
Q58742470Contribution of HIV Infection, AIDS, and Antiretroviral Therapy to Exocrine Pathogenesis in Salivary and Lacrimal Glands
Q48095233Current Anti-Integrin Therapy for Ocular Disease
Q39025675LFA-1/ICAM-1 Interaction as a Therapeutic Target in Dry Eye Disease
Q39069560Lifitegrast Ophthalmic Solution 5%: A Review in Dry Eye Disease
Q64106425Longitudinal changes in dry eye symptoms and signs following lifitegrast therapy and relationship to tear osmolarity
Q47268214Ocular Distribution and Pharmacokinetics of Lifitegrast in Pigmented Rabbits and Mass Balance in Beagle Dogs
Q58694745Safety and efficacy of lifitegrast 5% ophthalmic solution in contact lens discomfort
Q92236526Six months' treatment with lifitegrast in patients with moderate-to-severe symptomatic dry eye: a retrospective chart review

Search more.